DDU of Nebulisers

The delivered dose testing of a nebulisers is carried out to determine the total amount of drug a patient might be expected to receive during a treatment period, rather than through one inhalation. Given the mode of operation of nebulisers, well-defined tidal breathing profiles for specific patient types are specified for testing. The two tests specified in the Pharmacopoeias to characterise delivered dose, Active Substance Delivery Rate and Total Active Substance Delivered, are based on tidal flow conditions generated by a breathing simulator, as opposed to fixed flow rates.

DDU of Dry Powder Inhalers (DPIs)

Related Applications

We also offer a range of equipment for additional MDI testing application support:

Related Services

Related News & Resources

Copley introduces the new Patient Exhalation Simulator to help with inhaler development to understand the impact of poor patient technique.

12th September 2023

Find out more

Copley introduces the new Flow Rate Sensor, a dedicated device for inhaler testing systems.

27th June 2023

Find out more

The new DUSA Shaker™ DTS 100i from Copley: For faster, safer, more repeatable inhaler testing

8th February 2023

Find out more

Copley launches EnviroMate™, an efficient, benchtop environmental chamber for inhaler testing

14th September 2022

Find out more

Copley Scientific joins the Industries Forum of the Taskforce for Lung Health

22nd June 2021

Find out more

Copley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio

1st March 2021

Find out more

New e-Training service from Copley for pharmaceutical testing

29th January 2021

Find out more

Advancing the science of OINDPs: Copley Scientific joins IPAC-RS

28th February 2018

Find out more

Copley Scientific introduces improved test set-up for more representative inhaled product testing

5th August 2014

Find out more

More precise nebuliser testing as Copley Scientific launches NGI Cooler

29th April 2009

Find out more

Bridging the Gap: Enhancing the Clinical Realism of In Vitro OINDP Testing

View download

Understanding the Links Between Drug Delivery Route and In Vitro Test Methods

View download

Reducing Inhaler Testing Variability Through Test Environment Control

View download

Semi-Automating Inhaler Testing – A Good Idea, but Where to Start?

View download

Putting Inhalers to the Test

View download

A short Q&A with our CEO, Mark Copley, On Inhaled Product Testing

View download

Optimizing the Role of Automation in Variability Reduction Strategies For Delivered Dose Uniformity (DDU) and Aerodynamic Particle Size Distribution (APSD) Testing of Inhaled Drug Products

View download

The Regulatory Landscape for OINDPs – The Biggest Shake-up in A Generation?

View download

Optimizing the Application of In Vitro Test Methods for the Demonstration of Bioequivalence in Orally Inhaled Products

View download

Demonstrating Bioequivalence of Orally Inhaled Products

View download

Optimising the Application of In Vitro Test Methods for the Demonstration of BE in OIPs

View download